NCT07480941 2026-03-18
DUAL-CAR-NK-GB
Beijing Biotech
Phase 1 Recruiting
Clinical Trials
8 trialsNCT06186401 2026-03-16
Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells
University of California, San Francisco
Phase 1 Recruiting
NCT03152318 2026-03-04
rQNestin
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT05106296 2026-01-09
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
Augusta University
Phase 1 Recruiting
NCT02502708 2020-06-04
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
Lumos Pharma
Phase 1 Completed
NCT00990496 2018-05-02
A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM)
Milton S. Hershey Medical Center
Phase 1 Terminated
NCT02937844 2016-10-19
Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme
Beijing Sanbo Brain Hospital
Phase 1 Unknown
NCT02844062 2016-07-26
Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme
Beijing Sanbo Brain Hospital
Phase 1 Unknown